Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

43.24
Delayed Data
As of Jun 30
 +0.02 / +0.05%
Today’s Change
37.59
Today|||52-Week Range
73.91
-20.03%
Year-to-Date
Mylan Launches Generic Version of Glaxo's Avodart in U.S.
Jun 27 / Zacks.com - Paid Partner Content
Cancer doctors face next drug challenge
Jun 01 / FT.com - Paid Partner Content

Today’s Trading

Previous close43.22
Today’s open43.25
Day’s range42.47 - 43.37
Volume7,206,393
Average volume (3 months)5,123,860
Market cap$22.0B
Dividend yield--
Data as of 4:00pm ET, 06/30/2016

Growth & Valuation

Earnings growth (last year)-27.35%
Earnings growth (this year)+14.66%
Earnings growth (next 5 years)+11.41%
Revenue growth (last year)+21.91%
P/E ratio18.6
Price/Sales2.84
Price/Book2.17

Competitors

 Today’s
change
Today’s
% change
VRTXVertex Pharmaceutica...+1.02+1.20%
ZTSZoetis Inc+0.22+0.47%
ALXNAlexion Pharmaceutic...+2.59+2.27%
INCYIncyte Corp+1.25+1.58%
Data as of 4:02pm ET, 06/30/2016

Financials

Next reporting dateJuly 27, 2016
EPS forecast (this quarter)$1.14
Annual revenue (last year)$9.5B
Annual profit (last year)$847.6M
Net profit margin8.95%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Executive Director
Heather M. Bresch
President &
Executive Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts

Partner Offers

Search for Jobs